Article

[Thromboembolism risks in atrial fibrillation].

Service de Cardiologie B, Pôle CTVH, Hôpital Trousseau, Université François Rabelais, Tours, France.
Annales de cardiologie et d'angeiologie (impact factor: 0.21). 12/2009; 58 Suppl 1:S11-3. DOI:10.1016/S0003-3928(09)73390-6 pp.S11-3
Source: PubMed

ABSTRACT The atrial fibrillation is linked to an overmortality (x2), except in patients with lone atrial fibrillation. The severity of atrial fibrillation is due to the risk of thromboembolism event, especially stroke. This risk is very high in presence of rhumatismal mitral valve pathology or prosthetic valve. The annual risk of thromboembolism has been evaluated and the CHADS2 score defined from 0 to 6 In function of the CHADS2 score the risk of thromboembolism event is 1.9 to 18.2%/year. Other factors of thromboembolism accident are actually evaluated such as renal insufficiency, proteinuria. The main objective of atrial fibrillation treatment is the prevention of thromboembolism event. The antivitamin K agents proved their efficiency in term of mortality and morbidity justifying to identify the patients at risk of thromboembolism event.

0 0
 · 
0 Bookmarks
 · 
24 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

annual risk
 
antivitamin K agents
 
atrial fibrillation
 
atrial fibrillation treatment
 
CHADS2 score
 
factors
 
lone atrial fibrillation
 
main objective
 
overmortality
 
patients
 
renal insufficiency
 
rhumatismal mitral valve pathology
 
severity
 
thromboembolism
 
thromboembolism accident
 
thromboembolism event